Clinical trials: psoriasis
Psoriasis, Psoriatic Arthritis
Evaluating of New Screening Tool for Arthritis* in Psoriasis
This study evaluates a new screening tool for arthritis in psoriasis and compares its reliability with well-known screening tool (TOPAS 2).
- Trial name
- TUPAST (NCT04277832)
- Testing
- Questionary
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Bezmialem Vakif University
Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis
Safety and Efficacy study of AVT02 (Alvotech Biosimilar to Adalimumab), in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT03849404
- Testing
- Adalimumab
- Where
- 20 sites in Estonia, Georgia and 2 more
- Volunteers
- 413 people
- Sponsor
- Alvotech Swiss AG
Plaque Psoriasis
Understanding Participation Habits Among Plaque Psoriasis Patients
The study intends to investigate the personal experiences of plaque psoriasis patients who take part in a separate clinical study including a specific medication intervention.
- Trial name
- NCT06338358
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Psoriasis
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
The goal of this trial is to assess whether the efficacy of CMAB015 is similar to that of Secukinumab in patients with moderate-severe chronic plaque psoriasis.
- Trial name
- NCT06398652
- Testing
- CMAB015, Secukinumab
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Psoriasis
Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis
The primary objective of this study is to compare disease activity, as measured by PASI score, of two MEDI-507 dose levels (0.012 and 0.04 mg/kg) versus placebo administered by intravenous infusion every 2 weeks for a total of 8…
- Trial name
- NCT00192452
- Testing
- MEDI-507
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- MedImmune LLC
Psoriatic Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo and versus adalimumab (Humira®) in participants with moderately to…
- Trial name
- SELECT - PsA 1 (NCT03104400)
- Testing
- Adalimumab, Upadacitinib
- Where
- 345 sites in United States, Argentina and 44 more
- Volunteers
- 1,705 people
- Sponsor
- AbbVie
Psoriasis Vulgaris
Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D.
Patients will be screened up to 28 days before start of treatment. During the screening visit, the purpose and procedures of the study will be explained to potential patients and informed consent will be obtained.
- Trial name
- NCT02735187
- Testing
- Blue light treatment, Vitamin D
- Where
- Germany
- Volunteers
- 51 people
- Sponsor
- Philips Electronics Nederland BV
Psoriasis Vulgaris, UVB Phototherapy Burn
Effect Narrow-Band UVB Radiations
Narrow-band UVR affects Interleukin 17 which has a major role in the pathogenesis of psoriasis Vulgaris. the aim of this study to evaluate the serum levels of Interleukin 17 in psoriatic patients and compare with the levels in…
- Trial name
- UVB (NCT05647187)
- Testing
- Serum Interleukin 17 levels, NB-UVB
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- South Valley University
Nail Psoriasis
Nd:YAG Laser and Radiofrequency in Treatment of Fingernail Psoriasis
Compare the effect of Radiofrequency to long pulsed Nd:YAG 1064 nm laser in treatment of fingernail psoriasis.
- Trial name
- NCT05695833
- Testing
- Radiofrequency
- Volunteers
- 30 people
- Sponsor
- Cairo University
Atopic Dermatitis, Psoriasis
A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers
This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in healthy adult subjects.
- Trial name
- NCT05718921
- Testing
- YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Arthritis, Psoriatic
Study Evaluating the Safety of Enbrel (Etanercept)
The purpose of this study is to collect post-marketing information on the safety of Enbrel in Filipino patients.
- Trial name
- NCT00683384
- Testing
- Etanercept (Enbrel)
- Where
- Philippines
- Volunteers
- 93 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriasis
A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis
The purpose of this study is to determine whether DRM02 is safe and effective in the treatment of plaque psoriasis when applied twice daily for 6 weeks.
- Trial name
- NCT01993433
- Testing
- DRM02, Vehicle
- Where
- 2 sites in Canada
- Volunteers
- 23 people
- Sponsor
- Dermira, Inc.
Psoriasis
Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)
Protocol Title: A Phase 1, first-in-human, randomized, double-blind, single-dose, parallel-group, 3-arm study comparing the pharmacokinetic, safety, tolerability, and immunogenicity profiles of AVT04, EU approved Stelara®, and…
- Trial name
- NCT04744363
- Testing
- Stelara PFS
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Alvotech Swiss AG
Psoriasis
A Study of AK111 in Healthy Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled, single dose-escalation first-in human study to evaluate the safety, tolerability, PK, PD and immunogenicity of AK111 in healthy subjects following SC…
- Trial name
- NCT03622021
- Where
- New Zealand
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Akesobio Australia Pty Ltd
Psoriasis
TYK2 Inhibition in Paradoxical Psoriasis
Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or the joints.
- Trial name
- TYPP (NCT06281106)
- Testing
- Deucravacitinib
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Prof Curdin Conrad
Plaque Psoriasis
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
- Trial name
- NCT05172726
- Testing
- tapinarof cream, 1%
- Where
- 19 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Organon and Co
Psoriasis
Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
Psoriasis (PsO) is a chronic, disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques and is associated with high burden of illness that results in a negative impact on long-term health…
- Trial name
- NCT04818385
- Where
- 8 sites in Taiwan
- Volunteers
- 240 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Rituxan With or Without Methotrexate in Psoriatic Arthritis
The purpose of this study is to help determine the effectiveness of rituxan (with or without methotrexate) in the treatment of psoriatic arthritis.
- Trial name
- NCT00509678
- Testing
- Rituximab
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Swedish Medical Center
Psoriasis of Scalp, Psoriasis Vulgaris
Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis
A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis
- Trial name
- APRESCALP (NCT03553433)
- Testing
- Apremilast 30mg
- Where
- 4 sites in Switzerland
- Volunteers
- 90 people
- Sponsor
- University of Zurich
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
COMFI - a COMbined Fatigue Intervention
Background: Inflammatory arthritis (IA) encompasses autoimmune rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
- Conditions
- Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Spondyloarthritis (SpA), Inflammatory Arthritis
- Trial name
- COMFI (NCT06666452)
- Testing
- COMFI - a COMbined Fatigue Intervention
- Where
- 2 sites in Denmark, Sweden
- Volunteers
- 39 people
- Sponsor
- The Danish Center for Expertise in Rheumatology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.